Enanta Pharmaceuticals to Participate in Two Investor Conferences in May

Rhea-AI Summary

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in two investor conferences in May. The JMP Securities Life Sciences Conference fireside chat will be held on May 16 at 9:30 a.m. ET, and the RBC Capital Markets Global Healthcare Conference fireside chat will be held on May 17 at 2:05 p.m. ET. The webcasts will be accessible on Enanta's website, and replays will be available for at least 30 days.

WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in two investor conferences being webcast in May:

• JMP Securities Life Sciences Conference: Fireside Chat at 9:30 a.m. ET on May 16, 2023
• RBC Capital Markets Global Healthcare Conference: Fireside Chat at 2:05 p.m. ET on May 17, 2023

A live webcast of each event will be accessible by visiting the “Events and Presentations” section on the “Investors” page of Enanta’s website at www.enanta.com. Replays of the webcasts will be available following the presentations and will be archived for at least 30 days.

About Enanta Pharmaceuticals, Inc.
Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs for the treatment of viral infections. Enanta’s research and development programs include clinical candidates for the following disease targets: respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19) and hepatitis B virus (HBV). Enanta is also conducting research on a single agent targeting both RSV and human metapneumovirus (hMPV).

Enanta receives royalties from hepatitis C virus (HCV) products developed under its collaboration with AbbVie. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing chronic HCV infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET® (U.S.) and MAVIRET® (ex-U.S.) (glecaprevir/pibrentasvir). Please visit www.enanta.com for more information.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230509005465/en/

Media and Investors

Jennifer Viera

617-744-3848

jviera@enanta.com

Source: Enanta Pharmaceuticals, Inc.

FAQ

Which company will participate in the investor conferences in May?

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) will participate in the investor conferences in May.

When will the JMP Securities Life Sciences Conference fireside chat be held?

The JMP Securities Life Sciences Conference fireside chat will be held on May 16 at 9:30 a.m. ET.

When will the RBC Capital Markets Global Healthcare Conference fireside chat be held?

The RBC Capital Markets Global Healthcare Conference fireside chat will be held on May 17 at 2:05 p.m. ET.

Where can the webcasts be accessed?

The webcasts can be accessed on Enanta's website.

Will there be replays available for the webcasts?

Yes, replays of the webcasts will be available for at least 30 days.